Nab-paclitaxel and carboplatin combined with antiangiogenic drugs
Published: 05-03-2020| Version 1 | DOI: 10.17632/vdhjxp87mh.1
Contributor:
Description
We retrospectively investigated the efficacy and toxicity of NCA regimen in unresectable stage IIIC or IV melanoma patients who progressed on previous therapy. The NCA regimen consisted of nab-paclitaxel (260 mg/m2) and carboplatin(AUC=5) on day 1 and bevacizumab, 5 mg/kg IV every 2 weeks or endostatin 7.5mg/m2 days 1-14,Q28.